Innophos Highlights New Clinical Research About Oxyjun®
Cranbury, NJ – January 12, 2023 – Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of new clinical findings from ENovate Biolife highlighting Oxyjun®, a premium branded extract of Terminalia arjuna. Extracted from the bark of the Arjuna tree, Terminalia arjuna has traditionally been used for cardio protection purposes. The findings from this latest human clinical trial demonstrate advanced benefits in the areas of cardiac output and perceived reduction in physical fatigue in study subjects.
“Cardiac health is of the utmost importance for today’s consumers, and we are excited about the beneficial findings of Oxyjun® from this study,” said Dr. Bruce Abedon, R&D Senior Manager at Innophos and co-author of the study. “As the exclusive licensed distributor of Oxyjun® in North America, our team at Innophos is committed to providing the highest quality, science-backed products, and continuing our partnership with ENovate Biolife.”
The new study, published in the peer-reviewed Journal of Multidisciplinary Health, featured 72 male and female subjects ranging in age from 30-70 years old that took 400 mg of Oxyjun® daily for 56 days. Subjects were evaluated on both cardiac output based on left ventricular ejection fraction (the volume of blood flowing from the heart to the body with each beat) as well as their perceived level of physical fatigue based on a validated, multi-question Fatigue Severity Scale instrument.
Consumption of Oxyjun® resulted in numerous improvements in the health of subjects including:
- 6.28% increase in cardiac output (vs. 0.24% for placebo)
- 22.5% perceived reduction in physical fatigue (vs. 8.5% for placebo)
- No adverse events related to consumption of Oxyjun for any of the study participants
*These statements have not been evaluated by the Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.